37,100 Shares in Zoetis Inc. $ZTS Bought by Context Capital Management LLC

Context Capital Management LLC acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 37,100 shares of the company’s stock, valued at approximately $4,668,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis during the 4th quarter valued at about $25,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis in the fourth quarter worth approximately $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis in the third quarter worth approximately $31,000. Holos Integrated Wealth LLC bought a new stake in Zoetis during the fourth quarter valued at approximately $32,000. Finally, Elyxium Wealth LLC purchased a new stake in Zoetis during the fourth quarter valued at approximately $32,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 11,650 shares of company stock worth $886,384 over the last quarter. Insiders own 0.22% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $79.51 on Friday. The company has a market capitalization of $33.33 billion, a price-to-earnings ratio of 13.19, a PEG ratio of 1.24 and a beta of 0.75. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The stock’s 50-day simple moving average is $96.94 and its 200-day simple moving average is $114.22. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $167.38.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The recent analyst coverage split suggests some Wall Street firms still see value in Zoetis despite the recent selloff, which could help stabilize sentiment. Zoetis (ZTS) Stock Draws Fresh Price Target Split After Difficult Q1 Update
• Neutral Sentiment: Multiple law firms are urging investors who bought Zoetis shares between January 14, 2025 and May 6, 2026 to join or lead securities-fraud litigation ahead of the July 27 deadline; while procedural for now, the steady stream of notices keeps legal overhang in focus. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Neutral Sentiment: Additional class-action reminders from The Gross Law Firm, Bragar Eagel & Squire, and The Schall Law Firm add to the headline noise, but do not yet change Zoetis’s fundamentals on their own. ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit
• Neutral Sentiment: The lawsuits appear to center on alleged misrepresentations about weakening veterinarian adoption and prescription trends, which help explain why investors remain cautious after the company’s disappointing Q1 results. Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery
• Negative Sentiment: The legal overhang and repeated fraud allegations are a negative for sentiment and may keep pressure on Zoetis Inc. (NYSE: ZTS) until there is more clarity on the lawsuits and on whether the underlying business trends are improving. ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ZTS shares. BTIG Research reiterated a “buy” rating and set a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Stifel Nicolaus lowered their target price on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research report on Friday, May 22nd. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Citigroup lowered their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, UBS Group reduced their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $133.92.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.